Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

ResMed Inc.

Changes in Beneficial Ownership

Filed Oct 8, 2026Accepted Oct 8, 2026, 5:31 PM EDTFiling CIK 1485164Accession 0000943819-26-000085
Share

Structured filing — 4

form4.xml

Open full document ↗

Filing details

Report period
2026-10-07
Issuer
RESMED INC
Issuer CIK
0000943819
Trading symbol
RMD
Rule 10b5-1 indication
Checked

Reporting owner 1

Name
Farrell Michael J.
Reporting owner CIK
0001485164
Relationship
Director · Officer
Officer title
Chairman and CEO
Address
RESMED INC., 9001 SPECTRUM CENTER BLVD, SAN DIEGO, CA, 92123

Non-derivative transactions

Non-derivative transactions · 2 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
ResMed Common Stock2026-10-07M · Form 4[F1]4,991A146.34484,794D
ResMed Common Stock2026-10-07S · Form 4[F1]4,991D226.3349[F2]479,803D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
A
Acquired
D
Direct
S · Form 4
Sale on the market or privately

Non-derivative holdings

Non-derivative holdings · 1 reported row
SecurityAmount ownedOwnershipNature of ownership
ResMed Common Stock2,090ILisette and Michael Farrell Family Trust
Table key
I
Indirect

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
ResMed Common Stock Options146.342026-10-07M · Form 4[F1]4,991D02020-11-11[F3]2026-11-21ResMed Common Stock4,9914,993D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
D
Direct

Footnotes

F1
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.↩ 1↩ 2↩ 3
F2
This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price.↩ 1
F3
Represents date options first become exercisable. Options vest 1/3 per year↩ 1

Signature 1

Signed
/s/ Michael J. Farrell, Chairman and CEO
Date
2026-10-08

Company context

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

Current securities

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security HoldersNov 19, 2026
  2. 10-Q filingOct 30, 2026
  3. Results of Operations and Financial Condition · Other EventsOct 29, 2026
  4. ARS filingOct 1, 2026
  5. DEFA14A filingOct 1, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.